Orbis Medicines Launches with €26 Million Seed Financing to Transform Macrocycle Drug Development through Next-Generation Orally Dosable ‘nCycles’
Orbis Medicines, a leader in oral macrocycle drug discovery, today announces its launch with a €26 million financing led by global life sciences investor Novo Holdings and European life sciences venture firm Forbion.